Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSinclair Pharma Regulatory News (SPH)

  • There is currently no data for SPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completes £132m strategic disposal

17 Dec 2015 08:41

RNS Number : 3819J
Sinclair IS Pharma PLC
17 December 2015
 



 

Sinclair IS Pharma plc

("Sinclair" or the "Company")

Completes £132m strategic disposal of non-aesthetics business to Alliance Pharma plc

 

Creates a fast growth, high margin pure-play differentiated aesthetics company

 

· Delivering a product portfolio operating in fast growing markets underpinned by geographic expansion and new product introductions

· Highly differentiated aesthetics brands addressing unmet market need for effective, high quality, minimally-invasive treatments

· Simplified business structure with a strong balance sheet with pro forma net cash of £82m to support future growth

· The Company remains in an offer period

 

London, 17 December 2015 further to the announcement on 26 November 2015, Sinclair IS Pharma plc (SPH.L), ("Sinclair" or the "Company") the international specialty pharma company, is pleased to announce it has completed the strategic disposal of its non-aesthetics business to Alliance Pharma plc for a total upfront cash consideration of £132m as well as sales-related royalty payments relating to Flammacerium US.

 

The terms of the transaction announced on 26 November 2015 remain unchanged.

 

Sinclair is now a pure-play highly differentiated aesthetics company, operating in a high growth, self-pay market with high gross margin. Sinclair's balance sheet has now been transformed, leaving the Company with a pro-forma net cash position of £82m to invest in future growth opportunities and to cover milestone payments from historical acquisitions. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years.

 

As announced on 26 November 2015 the Company remains in an offer period under the framework provided by a formal sales process under the Takeover Code.

 

Tomorrow the Company will formally change its name to Sinclair Pharma plc, the TIDM will remain SPH.L.

 

For further information please contact:

 

Sinclair IS Pharma plc

Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

 

Rothschild

Tel: +44 (0) 20 7280 5000

Julian Hudson

 

Peel Hunt LLP (NOMAD and Broker)

Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson

 

Media enquiries

 

FTI Consulting

Tel: +44 (0) 203 727 1000

Ben Atwell

Brett Pollard

 

 

Notes to Editors:

 

About Sinclair IS Pharma plc - www.sinclairpharma.com 

Sinclair IS Pharma plc is an international company that operates in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. The group has an established sales and marketing presence in the leading EU markets' and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISPKODNFBDKFBD
Date   Source Headline
24th Sep 20182:13 pmRNSForm 8.3 - Sinclair Pharma Plc
24th Sep 20181:58 pmBUSForm 8.3 - Sinclair Pharma plc - Amendment
24th Sep 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
24th Sep 20187:00 amRNSForm 8.3 - Sinclair Pharma plc
24th Sep 20187:00 amBUSForm 8.3 - Sinclair Pharma plc
21st Sep 20183:48 pmRNSRobert Stuart Swanson-Form 8.3 Sinclair Pharma plc
21st Sep 20183:14 pmRNSForm 8.3 - Sinclair Pharma PLC
21st Sep 20182:18 pmRNSForm 8.3 - Sinclair Pharma PLC
21st Sep 20181:58 pmBUSForm 8.3 - Sinclair Pharma plc
21st Sep 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
21st Sep 20187:00 amRNSForm 8.3 - Sinclair Pharma plc
20th Sep 20183:06 pmRNSForm 8.3 - Sinclair Pharma Plc
20th Sep 20182:55 pmBUSForm 8.3 - Sinclair Pharma plc
20th Sep 20182:42 pmRNSForm 8.3 - Sinclair Pharma
20th Sep 20182:34 pmRNSForm 8.3 - Sinclair Pharma Plc
20th Sep 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
20th Sep 20188:52 amRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
20th Sep 20187:00 amRNSForm 8.3 - Sinclair Pharma PLC
19th Sep 20183:29 pmRNSHolding(s) in Company
19th Sep 20182:29 pmRNSForm 8.3 - [Sinclair Pharma PLC]
19th Sep 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
19th Sep 201810:29 amRNSForm 8.3 - SINCLAIR PHARMA PLC
19th Sep 20187:00 amRNSForm 8.3 - Sinclair Pharma plc
18th Sep 20182:55 pmRNSForm 8.3 - Sinclair Pharma Plc
18th Sep 20182:53 pmRNSForm 8.3 - Sinclair Pharma Plc
18th Sep 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
18th Sep 20189:36 amRNSForm 8.3 - SINCLAIR PHARMA PLC
18th Sep 20188:14 amRNSHolding(s) in Company
18th Sep 20188:02 amRNSRecommended Cash Offer for Sinclair Pharma plc
18th Sep 20188:01 amRNSRecommended Cash Offer for Sinclair Pharma plc
18th Sep 20187:00 amRNSForm 8.3 - Sinclair Pharma plc
17th Sep 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
17th Sep 20187:00 amRNSForm 8.3 - Sinclair Pharma plc
14th Sep 201812:08 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
14th Sep 20187:00 amRNSForm 8.3 - Sinclair Pharma plc
13th Sep 20181:49 pmRNSForm 8.3 - Sinclair Pharma plc
13th Sep 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
12th Sep 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
12th Sep 201810:35 amRNSForm 8.3 - SINCLAIR PHARMA PLC
12th Sep 20189:52 amRNSForm 8.3 - Sinclair Pharma Plc
12th Sep 20187:00 amRNSForm 8.3 - Sinclair Pharma PLC
11th Sep 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
11th Sep 20189:58 amRNSResponse to update re possible offer for Sinclair
11th Sep 20189:52 amRNSForm 8.3 - SINCLAIR PHARMA PLC
11th Sep 20189:46 amRNSUpdate re Possible Offer for Sinclair Pharma plc
10th Sep 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
7th Sep 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
6th Sep 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
5th Sep 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
4th Sep 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.